Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARBI vs ATACAND HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Treatment of hypertension,Off-label: Diabetic nephropathy, heart failure
Treatment of hypertension, for patients not adequately controlled on monotherapy.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Primarily metabolized by CYP2C9 and CYP3A4; undergoes dehydrogenation and decarboxylation.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
High (>99% bound to serum proteins, mainly albumin).
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Approximately 0.9 L/kg (total Vdss of about 86 L), indicating extensive distribution into tissues.
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Absolute bioavailability is about 15% due to extensive first-pass metabolism (CYP2C9, UGT1A3).
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
No dose adjustment is required for patients with mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease (ESRD), caution is advised; no specific dosing recommendations are available due to limited data. Avoid use in patients undergoing dialysis.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A). For moderate hepatic impairment (Child-Pugh class B), the recommended starting dose is 40 mg once daily; maximum dose is 40 mg once daily. EDARBI should not be used in patients with severe hepatic impairment (Child-Pugh class C).
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
Safety and efficacy in pediatric patients (<18 years) have not been established. Therefore, no dosing recommendation is provided.
Safety and efficacy not established in pediatric patients (<18 years).
No dose adjustment is required for elderly patients (≥65 years). However, as with all patients, initiate at 40 mg once daily; consider cautious titration due to potential greater sensitivity and increased risk of hypotension.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
No FDA boxed warnings.
None.
Fetal toxicity: Avoid in pregnancy; discontinue if pregnancy occurs,Hypotension in volume-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk in patients with renal impairment or on potassium-sparing diuretics,Avoid use in patients with bilateral renal artery stenosis
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Concomitant use with aliskiren in patients with diabetes,Hypersensitivity to edarbi or any component,Pregnancy
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
No significant food interactions. May be taken with or without food. Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes) and salt substitutes containing potassium, especially in patients with renal impairment or those on concomitant RAAS inhibitors or potassium-sparing diuretics.
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal renal damage, oligohydramnios, and skull ossification defects. Second and third trimester exposure: Increased risk for oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and anuria. Use is contraindicated in pregnancy, especially in second and third trimesters.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
No data on azilsartan medoxomil (EDARBI) excretion in human milk; effects on the breastfed infant and milk production are unknown. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio unknown.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
EDARBI is not recommended during pregnancy; if pregnancy is detected, discontinue as soon as possible. No specific dose adjustments have been established for use in pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure, but no data are available to guide dosing.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) with high receptor affinity and a long half-life (~11 hours), allowing once-daily dosing. It is a prodrug that is rapidly hydrolyzed to the active moiety azilsartan. Onset of action within 2 weeks; maximum effect may take 4-6 weeks. Monitor renal function and serum potassium, especially in patients with renal impairment, diabetes, or those taking NSAIDs or potassium-sparing diuretics. Avoid use in pregnancy (category D). Dose adjustment recommended for patients with hepatic impairment (Child-Pugh class B).
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Take exactly as prescribed, usually once daily, with or without food.,Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms such as dizziness, fainting, rapid heartbeat, or signs of kidney problems (e.g., swelling, decreased urination).,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose. Do not double the dose.,Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen without medical advice.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARBI vs ATACAND HCT, answered by our medical review team.
EDARBI is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARBI and ATACAND HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARBI is: EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.. The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARBI and ATACAND HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARBI is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal r. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.